Disease modification upon 2 weeks of tofacitinib treatment in a mouse model of chronic epilepsy
Hoffman O, Koehler J, Espina J, Patterson A, Gohar E, Coleman E, Schoenike B, Espinosa-Garcia C, Paredes F, Varvel N, Dingledine R, Maguire J, Roopra A. Disease modification upon 2 weeks of tofacitinib treatment in a mouse model of chronic epilepsy. Science Translational Medicine 2025, 17: eadt0527. PMID: 40106581, DOI: 10.1126/scitranslmed.adt0527.Peer-Reviewed Original ResearchConceptsTranscriptome dataJanus kinase/signal transducer and activatorKinase/signal transducer and activatorReverse cognitive deficitsJAK/STAT activationJAK/STAT3 signalingChronic epilepsyModel of temporal lobe epilepsySpontaneous seizuresMouse models of chronic epilepsyMouse modelCognitive deficitsSpatial memoryTransient inductionTemporal lobe epilepsyMouse model of temporal lobe epilepsyModel of chronic epilepsyLobectomy samplesDisease modificationTreat symptomsLobe epilepsyWhole tissueDrug treatmentEpileptogenic insultTofacitinib treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply